We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
251
CALL
GSK
GSK
$108B
– –
-5,040
Closed -$33.6M
GSK icon
252
PUT
GSK
GSK
$108B
– –
-70
Closed -$470K
GYRE icon
253
CALL
Gyre Therapeutics
GYRE
$668M
– –
-1
Closed -$187K
GYRE icon
254
Gyre Therapeutics
GYRE
$668M
– –
-45
Closed -$148K
HALO icon
255
CALL
Halozyme
HALO
$9.9B
– –
-700
Closed -$1.05M
IMNN icon
256
CALL
Imunon
IMNN
$6.43M
– –
-2
Closed -$2.33M
INCY icon
257
PUT
Incyte
INCY
$26B
– –
-187
Closed -$947K
INVA icon
258
CALL
Innoviva
INVA
$1.61B
– –
-282
Closed -$809K
IONS icon
259
Ionis Pharmaceuticals
IONS
$9.14B
– –
-13,157
Closed -$638K
LLY icon
260
Eli Lilly
LLY
$1.09T
– –
-40,700
Closed -$2.27M
LLY icon
261
PUT
Eli Lilly
LLY
$1.09T
– –
-407
Closed -$2.08M
LXRX icon
262
Lexicon Pharmaceuticals
LXRX
$1.04B
– –
-142,857
Closed -$1.8M
MBOT icon
263
Microbot Medical
MBOT
$113M
– –
-523
Closed -$1.04M
LITS
264
CALL
Lite Strategy Inc
LITS
$33M
– –
-14
Closed -$216K
LITS
265
Lite Strategy Inc
LITS
$33M
– –
-6,900
Closed -$1.1M
MNKD icon
266
MannKind Corp
MNKD
$1.21B
– –
-786,370
Closed -$22.4M
OEF icon
267
CALL
iShares S&P 100 ETF
OEF
$19.8B
– –
-5,000
Closed -$57.7M
OEF icon
268
PUT
iShares S&P 100 ETF
OEF
$19.8B
– –
-2,000
Closed -$23.1M
PRTA icon
269
Prothena Corp
PRTA
$448M
– –
-19,000
Closed -$613K
RIGL icon
270
Rigel Pharmaceuticals
RIGL
$712M
– –
-76,290
Closed -$2.17M
SPY icon
271
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
– –
-8,933
Closed -$165M
STAA icon
272
CALL
STAAR Surgical
STAA
$1.13B
– –
-676
Closed -$1.09M
STAA icon
273
PUT
STAAR Surgical
STAA
$1.13B
– –
-194
Closed -$314K
TGTX icon
274
TG Therapeutics
TGTX
$8.4B
– –
-66,000
Closed -$257K
VNDA icon
275
Vanda Pharmaceuticals
VNDA
$310M
– –
-146,350
Closed -$1.82M
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.